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SINCE its discovery in 1958 cyclophos-
phamide (CY) has been wiidely used in both
clinical and experimental animal studies
of cancer chemotherapy. Its disposition
in the most commonly used experimental
animal, the rat, has not, however, been
studied by mnodern techniques. Previous
investigators have relied upon several
relatively non-specific assay methods:
colorimetry (Friedman, 1967), whole-body
and micro-autoradiography (Gerhards &
Graul, 1970, 1971), or used CY labelled
with radioactive isotopes at various posi-
tions (Graul et al., 1967; Chandramouli &
Sivaramakrishnan, 1969; Torkelson et al.,
1974). The present study has used a
specific gas-chromatographic technique to
estimate the concentration of unchanged
CY in rat tissues. This has been compared
with the tissue concentration ofalkylating
metabolites of CY, as a preliminary to the
investigation of some of the pharmaco-
kinetic factors which determine CY acti-
vation.
Adult Wistar colony-bred white rats
(200-250 g) were randomized into groups
of 7, each containing 4 males and 3
females. Each rat received an i.p. injection
of 200 mg/kg cyclophosphamide (En-
doxanaR, W.B. Pharmaceuticals Ltd) in
09%o saline. Animals were killed by
cervical dislocation at 0 25, 0 5, 1, 2 and
3-5 h after dosing, when samples ofplasma
and organs (see Table) were taken. Each
organ was washed with physiological
saline, dried on filter paper to remove
excess saline, and weighed. They were then
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homogenized in 01N NaCl solution (1
ml/g tissue) using an ultrasonicator (Poly-
tron, Kinematica GmbH). The homo-
genates and plasma were stored at -20'C
until analysis. Homogenates were centri-
fuged to obtain a clear supernatant. CY
was estimated as its trifluoracetyl deriva-
tive by gas chromatography, using an
alkali flame ionisation detector by the
method of Jtima et al. (1978). Alkylating
activity was assayed in terms of nor-
nitrogen mustard equivalents, by a modi-
fication of the nitrobenzylpyridine (NBP)
colorimetric method of Friedman & Boger
(1961).
The results of these analyses are shown
in the Table and Figure.
The apparent first-order rate constants
(k) of the decline of the terminal phases
were obtained from least-squares linear
regression of In (plasma or tissue concen-
tration) against time, using a Compucorp
344 calculator. Regressions were per-
formed with the last 3 data points and the
last 4 points. The value ofk corresponding
to the greater correlation coefficient was
used to calculate the t, of disappearance
from the tissue (from t, = ln 2/k). The
mean values of t, for the tissues investi-
gated are shown in the Table.
The mean plasma t, of I1 h is com-
parable to estimates made from studies
using 14C-labelled CY of I 0 h (Weaver et
al., 1978). The estimate of -60 h from
32P-labelled ('Y studies (Chandramouli &
Sivaramakrishnan, 1969) is therefore un-
likely to be correct. The t. of CY in rats is
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TABLE.-Some pharmacokinetic parameters of cyclophosphamide (CY) in the ratfollowing
200 mg/kg i.p. injection (k=first order elimination rateconstant; r =correlationcoefficient
for log linear regression; t' = elimination half-life)
Tissue
Plasma
Brain
Heart
Lung
Liver
Stomachi
Spleen
Kidney
Muscle (biceps femoris)
Fat (perinepliric)
thus longer than in the mouse, where it is
0-2 h (Alberts etal., 1978) but much shorter
than in man (6-12-4 h: Juma et al., 1978).
Cohen & Jao (1970) have demonstrated
that the level of CY activating enzyme is
3 x higher in male rat liver than in the
female, and Cox (1979) has found that
cystitis due to CY congeners is less in
female rats than in males, and has sug-
gested that this results from a sex-related
difference in their transformation to
acrolein. Stratifying our groups of animals
by sex, the mean t4 for CY in females was
1*6 + 0-29 (s.d.) h and for males was 1-05 +
0*26 h This difference was significant at
the 5%o level (t= 2.63) and is therefore
concordant with the above observations
The area under the mean plasma con-
centration-time curve (AUC) for CY was
estimated by the linear trapezoidal rule,
with the addition of the term (mean
plasma concentration at 3-5 h/k) to
approximate the tail region of the curve
Assuming complete absorption of CY from
the peritoneal cavity, one may calculate
the total body clearance of CY from clear-
ance=dose/AUC, which was 728 ml/kg/h
As would be anticipated from the much
shorter t, in the rat than in man, this is a
much higher figure than the value of 61-4
ml/kg/h found in man by Juma et al.
(1978). It is interesting, therefore, that the
apparent volume of distribution (esti-
mated from clearance/k) was 1P17 1/kg,
which is comparable to the value of 0-78
]/kg found in man by these authors.
CY entered all tissues surveyed in this
study (see Table) confirming the results
of colorimetric (Friedman, 1967), radio-
labelled (Graul et al., 1967; Chandramouli
& Sivaramakrishnan, 1969) and auto-
radiographic (Gerhards & Graul, 1970)
studies. The distribution was slightly at
variance with the figures of the radio-
labelled CY study of Graul et al. (1967) in
that plasma CY concentration was higher
than that of the organs. However, the
highest organ concentration was found in
the kidneys, which agrees with their find-
ings, and may reflect the role of these
organs in drug elimination. The distribu-
tion of CY between the different tissues
was similar to that reported from the
radiolabelled studies mentioned pre-
viously.
The t. of CY in liver is considerably
longer than in plasma. Since metabolic
activation ofCY occurs in the liver (Cohen
& Jao, 1970) this would imply that these
enzyme-mediated steps are the rate-
linmiting process in CY elimination by this
organ. In other tissues the t, passively
reflects the plasma t,, although it is in-
teresting that in the two other tissues
(lung and kidney) in which the tz was
appreciably longer than in plasma, somne
CY metabolism has been detected (Brock
& Hohorst, 1967).
Determination of alkylating activity by
the NBP reaction gives an approximate
indication of CY activation, though there
is no direct correlation between total
k (h-1)
0 62
0 79
0 70
0 45
0 38
0 63
0 67
0 49
0-71
1-11
r
-0 988
- 0 983
- 0 980
-0 919
- 0-954
- 0 987
- 0 975
- 0 993
- 0 998
-0 960
t, (h)
1-1
0 9
1-0
1 5
1.9
1-1
1-0
1 4
1-0
0 6
Mean peak
concentration
(CY jug/g)
109-9
17 3
30 5
14 6
27 6
20 0
25 7
34 0
16 7
10-3
Time to peak
concentration
(h)
1-0
0 5
0 5
0 5
0 25
0 5
0 25
0 25
0 5
0 5
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FIG.-Upper panel: mean CY concentration
in rats following i.p. injection of 200 mg/kg
CY in plasma (*), liver (*), kidney ( x )
and spleen (0). Lower panel: NBP alkylat-
ing activity in terms of nor-nitrogen mus-
tard equivalents (nM/ml extract) for the
same organs. Each point represents mean of
7 animals.
NBP-alkylating activity and cytotoxicity.
The CY metabolite acroleinforexample, is
highly cytotoxic but has no alkylating
activity (Alarcon & Meienhofer, 1971). The
figure shows the relationship between the
alkylating activity in extracts of liver,
spleen and kidney and the concentration
ofunchanged CY. As might be anticipated,
there is little correlation between the two.
It is, however, clear that there is a very
rapid entry of alkylating metabolites into
the tissues examined following injection
of CY. This presumably results partly
from the metabolism of the drug on its
first passage through the liver following
absorption of CY into the hepatic portal
vein tributaries draining the peritoneum.
The increased concentration of alkylating
substances found in the kidney at 3-5 h
probably reflects the elimination of alkyla-
ting metabolites in the urine (Torkelson
et al., 1974) since over 75% of the isotope
from 32P-CY is eliminated in the urine in
5 h (Chandramouli & Sivaramakrishnan,
1969).
No corresponding data on the distribu-
tion of CY in human tissues has been
gathered, though Graul et al. (1967) have
shown that the drug can penetrate into
cerebral tumours. No conclusions may
therefore be made as to the appropriate-
ness of the rat as a model for CY distribu-
tion in man. Pharmacokinetically, how-
ever, although the systemic clearance of
CY is greater in the rat than in man, the
apparent volume of distribution (which
does not of course correspond to an actual
anatomical or physiological space) is com-
parable between the two species.
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